Propensity scores were computed using pooled patient-level covariate matrices across all participating healthcare organizations, and logistic regression was implemented via scikit-learn in Python (C = 1000, minimal L2 regularization)
Depression and obesity share bidirectional relationshipsweight gain can worsen mood, and depression can impede weight loss efforts
Safety and toxicity data are lacking for lipophilic (hydrophobic) garlic preparations, but some of their constituents have been shown to interfere with drug-metabolizing enzymes and transporters (see Drug interactions)
Maintaining adequate nutrition is paramount, even with reduced appetite
For a list of other modifications, click here
Patients whose primary goal is maximum weight loss and who want the drug with the strongest efficacy data Those who have plateaued on semaglutide and need a more potent treatment Adults with obesity and obstructive sleep apnea (the only FDA-approved pharmacotherapy for OSA) Type 2 diabetes patients who need stronger HbA1c reduction beyond what semaglutide can provide Patients for whom insurance covers tirzepatide at comparable or lower cost to semaglutide Who should choose semaglutide
